Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209934 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24469367 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25597040 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25599185 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21699485 | 1.00 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25668291 | 0.86 | XIAP (0.36) | — | |
| SCHEMBL22192668 | 0.84 | DPP4 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19201191 | 0.83 | FFAR2 (0.32) | — | |
| SCHEMBL23105983 | 0.83 | — | — | |
| SCHEMBL19201193 | 0.83 | FFAR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023002415-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) TREATMENT | Magenta Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2020219964-A1 | CONDITIONING METHODS FOR GENE THERAPY | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219770-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219959-A1 | ANTI-CD45 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219748-A2 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219774-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219775-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | ALDH1A1 3021/4885SMN1; SMN2 3263/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885SMN1; SMN2 2500/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ALDH1A1 3311/4885SMN1; SMN2 2012/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ALDH1A1 1924/4885SMN1; SMN2 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.